Adrenaline (epinephrine) IV infusion

Alert	1:10,000 (1 mg/10 mL) ampoule is the prefer	ed preparation for adrenaline infusion.		
Indication	Treatment of hypotensive shock with or without myocardial dysfunction.			
Action	 Catecholamine with alpha and beta adrenergic actions. Haemodynamic effects are dose dependent: At low doses of 0.01–0.1 microgram/kg/minute primarily stimulates cardiac and vascular beta 1- and beta 2-adrenoreceptors leading to increased inotropy, chronotropy, conduction velocity and peripheral vasodilation. At doses greater than 0.1 microgram/kg/minute adrenaline also stimulates vascular and cardiac alpha 1-receptors causing vasoconstriction and increased inotropy. The net effects are increases in blood pressure and systemic blood flow caused by the drug-induced increases in systemic vascular resistance (SVR) and cardiac output.¹ 			
Drug Type	Inotropic vasopressor.			
Trade Name	Aspen Adrenaline 1: 10,000 Adrenaline Acid Tartrate injection; Adrenaline 1:1,000 Adrenalin Acid Tartrate injection.			
Presentation	1 mg/10 mL or 1:10,000 ampoule [100 microgram/mL] 1 mg/mL or 1:1,000 ampoule [1000 microgram/mL]			
Dosage / Interval	Low dose: 0.05–0.1 microgram/kg/minute High dose: 0.1–1 microgram/kg/minute			
Route	Continuous IV infusion.			
Preparation/Dilution	Preparation using 1:10,000 (1 mg/10 mL) ampoule			
	LOW CONCENTRATION IV infusion Infusion dose	Prescribed amount		
	1 mL/hour = 0.05 microgram/kg/minute	150 microgram/kg adrenaline and make up to 50 mL		
	Draw up 150 microgram/kg [1.5 mL/kg] of 1:10,000 adrenaline and add glucose 5%, glucose 10% or sodium chloride 0.9% to make a final volume of 50 mL with a concentration of 3 microgram/kg/mL. Infusing at a rate of 1 mL/hour = 0.05 microgram/kg/minute. HIGH CONCENTRATION IV infusion			
	Infusion dose	Prescribed amount		
	1 mL/hour = 0.2 microgram/kg/minute	600 microgram/kg adrenaline and make up to 50 mL		
	Draw up 600 microgram/kg [6 mL/kg] of 1:10,000 adrenaline and add glucose 5%, glucose 10% or sodium chloride 0.9% to make a final volume of 50 mL with a concentration of 12 microgram/kg/mL. Infusing at a rate of 1 mL/hour = 0.2 microgram/kg/minute. For infants requiring fluid restriction consider: VERY HIGH CONCENTRATION IV infusion*			
	Infusion dose	Prescribed amount		
	1 mL/hour = 0.4 microgram/kg/minute	1200 microgram/kg adrenaline and make up to 50 mL		
	Draw up 1200 microgram/kg [12 mL/kg] of 1:10,000 adrenaline and add glucose 5% ONLY to make a final volume of 50 mL with a concentration of 24 microgram/kg/mL. Infusing at a rate of 1 mL/hour = 0.4 microgram/kg/minute. *Stability data only available for 5% glucose for very high concentration.			

	Preparation using 1:1,000 (1 mg/mL : 1:1000 (1 mg/mL) ampoule is generated) ampoule – Occasionally used for infants>4 k rally not kept in the NICUs		
	LOW CONCENTRATION IV infusion			
	Infusion dose	Prescribed amount		
	1 mL/hour = 0.05 microgram/kg/minute	150 microgram/kg adrenaline and make up to 50 mL		
	Draw up 150 microgram/kg [0.15 mL/kg] of 1:1000 adrenaline and add glucose 5%, glucose 10% or sodium chloride 0.9% to make a final volume of 50 mL with a concentration of 3 microgram/kg/ml Infusing at a rate of 1 mL/hour = 0.05 microgram/kg/minute.			
	HIGH CONCENTRATION IV infusion			
	Infusion dose	Prescribed amount		
	1 mL/hour = 0.2 microgram/kg/minute	600 microgram/kg adrenaline and make up to 50 mL		
	Draw up 600 microgram/kg [0.6 mL/kg] of 1:1000 adrenaline and add glucose 5%, glucose 10% or sodium chloride 0.9% to make a final volume of 50 mL with a concentration of 12 microgram/kg/n Infusing at a rate of 1 mL/hour = 0.2 microgram/kg/minute. For infants requiring fluid restriction consider: VERY HIGH CONCENTRATION IV infusion*			
	Infusion dose	Prescribed amount		
	1 mL/hour = 0.4 microgram/kg/minute	1200 microgram/kg adrenaline and make up to 50 mL		
		1:1000 adrenaline and add glucose 5% ONLY to make a of 24 microgram/kg/mL. Infusing at a rate of 1 mL/hour		
Administration	Continuous intravenous infusion via a central line. Use with caution via a peripheral line.			
Monitoring	Continuous heart rate, ECG and blood pressure monitoring preferable. Assess urine output and peripheral perfusion frequently. Observe IV site closely for blanching and extravasation.			
Contraindications	Arrhythmia and tachyarrhythmia. Cardiovascular disease resulting in arterial narrowing including cerebrovascular disease, coronary artery disease and digital ischaemia. Phaeochromocytoma. Thyrotoxicosis. Glaucoma. Known hypersensitivity to sympathomimetic amines.			
Precautions	Ensure adequate circulating blood volume prior to commencement. Adrenaline is a potent chronotrope and vasopressor – may cause excessive tachycardia, severe hypertension and ventricular arrhythmias. Adrenaline may cause lactic acidosis and hyperglycaemia.			
Drug Interactions	Hypotension may be observed with concurrent use of vasodilators such as glyceryl trinitrate, nitroprusside and calcium channel blockers.			

NMF Consensus Group Adrenaline (epinephrine) IV Infusion This is a printed copy refer to the electronic system for most up to date version

and bradycardia.

Digital ischaemia.

Tachycardia and arrhythmia.

May cause hypokalaemia.

Systemic hypertension especially at higher doses.

Tissue necrosis at infusion site with extravasation.

5% glucose for very high concentration.

Adverse Reactions

Compatibility

Concurrent use of digitalis glycosides may increase the risk of cardiac arrhythmias.

Concurrent use of IV phenytoin with adrenaline may result in dose dependent, sudden hypotension

Fluids: Glucose 5%, glucose 10%, Hartmann's, sodium chloride 0.9%. Stability data only available for

Adrenaline (epinephrine) IV infusion

Y-site: Amino acid solutions. Amiodarone, anidulafungin, atracurium, bivalirudin, caspofungin, cisatracurium, dexmedetomidine, dobutamine, dopamine, ethanol, fentanyl, glyceryl trinitrate, heparin sodium, milrinone, morphine sulfate, pancuronium, potassium chloride, ranitidine, remifentanil, sodium nitroprusside, tigecycline, tirofiban, vecuronium.
Fluids: Sodium bicarbonate.
Y-site: Aciclovir, aminophylline, ampicillin, atropine, azathioprine, calcium chloride, calcium gluconate, cefalotin, chloramphenicol, digoxin, ergometrine, ganciclovir, hyaluronidase ⁻ , hydrocortisone sodium succinate, indomethacin, phenobarbitone sodium, sodium bicarbonate, thiopentone, vancomycin.
No information: Adrenaline HCL is compatible with noradrenaline bitartrate but no stability data is available for Adrenaline acid tartrate and noradrenaline bitartrate
Ampoule: Store below 30°C. Protect from light. Diluted solution: Stable for 24 hours below 25°C.
Ampoule: Store below 25°C. Protect from light. Discard remainder after use.
Ensure adrenaline has a "dedicated" line to avoid accidental bolus. Do not use as a side line with maintenance fluids. Discard if exhibiting colour change.
Efficacy: Treatment of hypotension in preterm infants: A single study of adrenaline 0.125–0.5 microgram/kg/minute versus dopamine 2.5–10 microgram/kg/minute reported they are equally effective at treating hypotension and increasing cerebral blood flow in very preterm infants. Adrenaline is associated with worse acid base status and increased hyperglycaemia. No difference in clinical outcomes was reported. [1–3] A single study of adrenaline 0.125, 0.250, 0.375, 0.5 microgram/kg/minute versus dopamine 5, 10, 15, 20 microgram/kg/minute reported dopamine reduced left ventricular output (LVO) 10% compared to a 14% increase in LVO with adrenaline. Dopamine and adrenaline caused significant increases in mean BP and pulmonary artery pressure. (LOE II, GOR C)
Infants and children with septic shock: Early administration of adrenaline 0.1–0.3 microgram/kg/minute was associated with increased survival compared to dopamine. [4] (LOE II, GOR B)
Vasopressors for hypotensive shock (newborns excluded): In treatment of hypotensive shock beyond the newborn period, there was no difference in mortality comparing adrenaline and other vasopressors (noradrenaline, noradrenaline and dobutamine, or noradrenaline and dopexamine). [5] (LOE I, GOR B)
Summary: Adrenaline may be used in hypotensive neonates with vasodilatory shock with or without myocardial dysfunction, particularly those with septic shock or unresponsive to other inotropes. (LOE II, GOR B)
Safety: Adrenaline may be associated with worse acid base status and increased hyperglycaemia.[3] Adrenaline is a potent vasoconstrictor. [6]
Pharmacokinetics: The onset of action is rapid and after intravenous infusion the half-life is approximately 5–10 minutes. [7] However, the half-life of intravenous adrenaline has not been reported in sick newborn infants. The plasma half-life of intratracheal adrenaline for newborn resuscitation is likely to average approximately50 minutes.[8]
1. Pellicer A, Bravo MDC, Madero R, Salas S, Quero J, Cabañas F. Early systemic hypotension and vasopressor support in low birth weight infants: Impact on neurodevelopment. Pediatrics. 2009;123:1369-76.

NMF Consensus Group Adrenaline (epinephrine) IV Infusion Page 3 of 4 This is a printed copy refer to the electronic system for most up to date version

Adrenaline (epinephrine) IV infusion

- 2. Pellicer A, Valverde E, Elorza MD, Madero R, Gayá F, Quero J, Cabañas F. Cardiovascular support for low birth weight infants and cerebral hemodynamics: A randomized, blinded, clinical trial. Pediatrics. 2005;115:1501-12.
- 3. Valverde E, Pellicer A, Madero R, Elorza D, Quero J, Cabanas F. Dopamine versus epinephrine for cardiovascular support in low birth weight infants: analysis of systemic effects and neonatal clinical outcomes. Pediatrics. 2006;117:e1213-22.
- 4. Ventura AMC, Shieh HH, Bousso A, Góes PF, Fernandes IDCFO, De Souza DC, Paulo RLP, Chagas F, Gilio AE. Double-blind prospective randomized controlled trial of dopamine versus epinephrine as first-line vasoactive drugs in pediatric septic shock. Critical Care Medicine. 2015;43:2292-302.
- 5. Havel C, Arrich J, Losert H, Gamper G, Mullner M, Herkner H. Vasopressors for hypotensive shock. The Cochrane database of systematic reviews. 2011:CD003709.
- 6. Noori S, Seri I. Neonatal blood pressure support: the use of inotropes, lusitropes, and other vasopressor agents. Clinics in perinatology. 2012;39:221-38.
- 7. Fitzgerald GA, Barnes P, Hamilton CA, Dollery CT. Circulating adrenaline and blood pressure: the metabolic effects and kinetics of infused adrenaline in man. European journal of clinical investigation. 1980;10:401-6.
- 8. Schwab KO, von Stockhausen HB. Plasma catecholamines after endotracheal administration of adrenaline during postnatal resuscitation. Archives of disease in childhood Fetal and neonatal edition. 1994;70:F213-7.
- 9. Young TE, Mangum B [2008]. Neofax: A manual of drugs used in neonatal care. Acorn Publishing, Inc. Raleigh, NC 27619
- 10. Australian Injectable Drugs Handbook, 6th Edition, Society of Hospital Pharmacists of Australia 2014.

Original version Date: 31/03/2016	Author: NMF Consensus Group
Current Version number: 1.2	Current Version Date: 30/11/2017
Risk Rating: Medium	Due for Review: 30/11/2020
Approval by: As per Local policy	Approval Date:

Authors Contribution

Original author	David Osborn
Evidence Review	David Osborn
Content review of the current version	Srinivas Bolisetty, David Osborn, Eszter Jozsa, Nilkant Phad, Cindy Chen
Nursing Review	Eszter Jozsa
Pharmacy Review	Jing Xiao, Mariella De Rosa, Ushma Trivedi, Cindy Chen
Final content and editing review of the original	Ian Whyte
Electronic version	Mariella De Rosa, Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty